Bristol's Blenoxane indicated for prevention of recurrent pleural effusions and treatment of MPEs.
BRISTOL BLENOXANE INDICATED FOR PREVENTION OF RECURRENT EFFUSIONS as well as treatment of pleural effusions associated with cancers, final product labeling states. "Blenoxane is effective as a sclerosing agent for the treatment of malignant pleural effusions and prevention of recurrent pleural effusions," the label says. Blenoxane (bleomycin) was approved for the supplemental indication Feb. 20 based on a literature review ("The Pink Sheet" Feb. 26, T&G-3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth